Gabapentin as add-on treatment for somatoform disorder: a case report

Clin Neuropharmacol. 2012 Jan-Feb;35(1):45-6. doi: 10.1097/WNF.0b013e31823e669b.

Abstract

Somatoform disorder is a relatively common and severe disorder for which pharmacotherapy has been minimally studied. We report a case of 30-year-old woman with treatment-resistant somatoform disorder that was successfully treated with add-on treatment of gabapentin. Our result showed that gabapentin 1800 mg/day could be tried in case of treatment-resistant somatoform disorder as an add-on strategy. However, controlled trials are needed to investigate the effectiveness of gabapentin in the management of this condition.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Amines / therapeutic use*
  • Anticonvulsants / therapeutic use
  • Antimanic Agents / therapeutic use
  • Cyclohexanecarboxylic Acids / therapeutic use*
  • Female
  • Gabapentin
  • Humans
  • Psychiatric Status Rating Scales
  • Somatoform Disorders / drug therapy*
  • gamma-Aminobutyric Acid / therapeutic use*

Substances

  • Amines
  • Anticonvulsants
  • Antimanic Agents
  • Cyclohexanecarboxylic Acids
  • gamma-Aminobutyric Acid
  • Gabapentin